Cellectis S.A. (CLLS)
Oxford Ledge is still expanding full research coverage of CLLS. A live quote, fundamentals, and analysis are available in the app; the SEC-sourced material below is what we currently have indexed here.
Business summary
The company develops novel CAR T-cell therapies with AstraZeneca partnership influence and faces evolving regulatory requirements across multiple oversight bodies.
SEC filings
- 6-K Interim report (foreign private issuer) 2026-06-25
- 6-K Interim report (foreign private issuer) 2026-06-11
- 6-K Interim report (foreign private issuer) 2026-06-09
- 6-K Interim report (foreign private issuer) 2026-05-21
- 6-K Interim report (foreign private issuer) 2026-05-20
Source: SEC EDGAR.
Insider activity
3 recent insider (SEC Form 4) filings on record for CLLS. View the transactions in the terminal.
Source: SEC EDGAR (Form 4).
- Open CLLS in the Oxford Ledge terminal — live quote, chart, and analysis in the app.
- Browse the covered-stock index
- Learn to analyze stocks yourself
The material above is drawn from public SEC EDGAR filings and is provided for educational purposes, not as investment advice. Live pricing and fundamentals are available in the terminal.